Short Interest in Inhibrx, Inc. (NASDAQ:INBX) Expands By 5.8%

On December 18th, 2024, it was reported that Inhibrx, Inc. (NASDAQ:INBX) experienced a notable increase in short interest during November. By the end of the month, on November 30th, the short interest had grown to 1,090,000 shares, reflecting a 5.8% rise from 1,030,000 shares observed on November 15th. This amount indicates that approximately 11.0% of the company’s stock is currently sold short. With an average daily trading volume of 84,700 shares, the short-interest ratio now stands at 12.9 days.

Insider Activity at Inhibrx

In addition to changes in short interest, there has been recent insider trading activity at Inhibrx. On November 19th, Director Jon Faiz Kayyem acquired 69,686 shares of the company's stock for an average price of $14.23 per share, totaling about $991,631.78. Following this transaction, the director holds 51,093 shares in Inhibrx, valued at approximately $727,053.39. This purchase signifies a -374.80% increase in his ownership position. Details of this insider transaction have been filed with the Securities and Exchange Commission and can be accessed through the appropriate legal channels. Insiders as a whole hold about 22.20% of the total shares in the company.

Recent Stock Performance

As for the trading performance, Inhibrx (NASDAQ:INBX) opened at $14.55 on the most recent Wednesday. The company's stock has a 50-day moving average of $15.33 and a 200-day moving average of $14.78. Over the past year, the stock has seen a low of $10.80 and a high of $18.95.

About Inhibrx

Inhibrx, Inc. is a biopharmaceutical company that focuses on developing a range of innovative biologic therapies. One of their prominent therapeutic candidates is INBRX-101, which is an alpha-1 antitrypsin (AAT)-Fc fusion protein currently undergoing Phase 1 clinical trials aimed at treating patients with AAT deficiency.

Inhibrx, Stocks, ShortInterest